US62855J1043
US62855J1043
Myriad Genetics, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 412.25M EUR | 545.88M EUR | 424.8M EUR | 575.03M EUR |
Enterprise Value | 497.03M EUR | 545.88M EUR | 511.9M EUR | 635.23M EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | -7.31x | -- | -- | -- |
Price to Sales | 0.51x | 0.89x | 0.51x | 0.7x |
Price to Book | 1.36x | -- | 1.26x | 1.56x |
EV/Revenue | 0.62x | 0.89x | 0.62x | 0.77x |
EV/EBITDA | -12.33x | -- | -- | -- |
Price to FCF (P/FCF) | 22.67x | -- | -- | -- |
EV/FCF | 27.33x | -- | -- | -- |
FCF Yield | 4.41% | -0.49% | -5.46% | -4.45% |